Prof Thomas Powles (Barts Cancer institute, London) and Prof Shahrokh F. Shariat (Vienna General Hospital, Austria) meet at ASCO 2018 to discuss the current patient eligibility changes within immuno-oncology following new guidance from EMA/FDA and share their thoughts on emerging neoadjuvant data with checkpoint inhibitors following some investigator initiated trials.
Both experts share their views on recently presented data on IDO1 inhibitors and pan-FGFR kinase inhibitors and signpost that future management of urothelial cancers front line may involve combination of therapies of PDL-1 with PARP or CTLA-4 inhibitors.
|Atezolizumab and pembrolizumab in platinum refractory bladder cancer|
|Prospects for CTLA4 and IDO combinations|
|FGFR inhibitors in clinical trials|
|Upcoming combinations for bladder cancer|
|Adjuvant and neoadjuvant therapies|
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).